EIGRライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (11 4月 2024 @ 05:00):

Stats
本日の出来高	129 682
平均出来高	120 792
時価総額	2.55M
EPS	$0 ( 2024-04-04 )
次の収益日	( $-5.40 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0300
ATR14	$0.988 (25.01%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-02	Kayne Richard A	Buy	23 398	Common Stock
2023-11-01	Kayne Richard A	Buy	100 000	Common Stock
2023-10-31	Kayne Richard A	Buy	130 509	Common Stock
2023-10-31	Kayne Richard A	Buy	12 345	Common Stock
2023-10-31	Kayne Richard A	Buy	11 987	Common Stock

INSIDER POWER
57.19
Last 89 transactions
Buy: 3 414 696 \| Sell: 449 818

ボリューム相関

長: -0.41 (neutral)

短: 0.03 (neutral)

Signal:(55.872) Neutral

Eiger BioPharmaceuticals 相関

10 最も正の相関
STER	0.953
INCR	0.94
RUBY	0.937
JAGX	0.936
PRAX	0.935
AGLE	0.934
DIBS	0.934
EMBK	0.93
RMRM	0.929
CCSI	0.926

10 最も負の相関
LWAC	-0.921
SGEN	-0.914
TIG	-0.912
MTSI	-0.91
TSBK	-0.907
IMRA	-0.905
MPRA	-0.904
SRAC	-0.893
PUCKU	-0.889
MTCR	-0.885

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Eiger BioPharmaceuticals 相関 - 通貨/商品

0.01
( neutral )

-0.70
( moderate negative )

-0.23
( neutral )

-0.33
( neutral )

0.71
( moderate )

-0.06
( neutral )

Eiger BioPharmaceuticals 財務諸表

Annual	2023
収益:	$15.77M
総利益:	$15.75M (99.85 %)
EPS:	$-50.78

FY	2023
収益:	$15.77M
総利益:	$15.75M (99.85 %)
EPS:	$-50.78

FY	2022
収益:	$13.48M
総利益:	$11.65M (86.38 %)
EPS:	$-69.74

FY	2021
収益:	$12.14M
総利益:	$11.40M (93.86 %)
EPS:	$-1.000

Financial Reports:

No articles found.

Eiger BioPharmaceuticals

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.